Study of HC022 for lupus and lupus skin disease
Part of Immune system & allergy, Skin clinical trials.
This early-phase study tests a new medicine called HC022 for people with lupus (SLE) or lupus skin disease (CLE). The goal is to check its safety and see if it helps reduce symptoms, and the study will monitor you closely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with lupus (SLE) or lupus skin disease (CLE).
- You are willing to use reliable birth control and not plan a pregnancy during the study and for 6 months after.
- You do not have severe kidney or brain involvement from lupus.
- You do not have another autoimmune disease (except Sjogren's syndrome).
- You are generally healthy apart from lupus, and have not had frequent serious infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called 626 for people with systemic lupus erythematosus (SLE). It aims to see if the drug is safe and effective at reducing disease activity.
This study tests a new investigational drug called SCTC21C for people with moderate-to-severe systemic lupus erythematosus (SLE). The goal is to see if the drug can help control lupus symptoms and reduce disease activity.
This study tests an experimental medicine called VENT-03 to see if it can improve skin lupus symptoms in adults. It compares VENT-03 against a placebo (a pill with no active drug) and includes a longer-term option where everyone can get the real drug. The goal is to find a new treatment for people whose lupus affects their skin.
This trial tests a new treatment for people with active lupus who haven't responded well to steroids and at least two other immune-suppressing drugs, including a biologic. It aims to find a better option for controlling lupus symptoms.
This trial tests an experimental drug called ICP-488 for people with active cutaneous lupus erythematosus (CLE), a type of lupus that affects the skin. It aims to see if the drug can reduce skin inflammation and improve symptoms.
This study tests an investigational drug that targets a protein involved in lupus. The goal is to see if it can reduce lupus activity and improve symptoms.
Hear when a new Cutaneous Lupus Erythematosus (CLE) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.